Medicare Secondary Payer Recovery Portal enhancements ease payment process

Enhancements to the Medicare Secondary Payer Recovery Portal (MSPRP) have been announced by CMS that address electronic payment capabilities for identified Non-Group Health Plan (NGHP) conditional payment debt. CMS publicized the enhancements during a March 13, 2019, webinar.

This welcome enhancement, effective April 1, 2019, is more efficient and expedient, as opposed to the current process of sending reimbursement checks via the mail. Additionally, the payments have more visibility with tracking to ensure the payment is accurately applied. No additional user access or authorizations are required.

Read moreMedicare Secondary Payer Recovery Portal enhancements ease payment process

What you need to know about naloxone

What is naloxone? Naloxone is an opioid antagonist that displaces opioids from receptors in the brain, reversing the effects of opioid analgesics, including their life-threatening effects. Naloxone is commercially available by nasal spray (i.e., Narcan® Nasal Spray), solution for injection and an auto-injector (i.e., Evzio®). Currently, naloxone products are only available by prescription. Naloxone is … Read moreWhat you need to know about naloxone

Changes influencing Medicare Secondary Payer compliance go into effect April 1, 2019

In accordance with the SSN Fraud Prevention Act of 2017, the COB&R program will mask the SSN and SSN-portion of the HICN, on all outgoing letters as of April 1, 2019. The first five digits of the SSN will be masked with asterisks (e.g., *****1234A). All outgoing hardcopy and electronic letters will be included in this … Read moreChanges influencing Medicare Secondary Payer compliance go into effect April 1, 2019

FDA advisory committees recommend approval of esketamine nasal spray for treatment-resistant depression

Cross-posted from our Optum Insights blog. Two advisory committees of the U.S. Food and Drug Administration (FDA) recently voted to approve esketamine nasal spray for the treatment of adults with treatment-resistant depression (TRD), which is typically defined as failing trials of at least two antidepressant treatments for major depressive disorder. Esketamine is chemically related to … Read moreFDA advisory committees recommend approval of esketamine nasal spray for treatment-resistant depression